Overview Dividends

(AMN) AMN Healthcare - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0017441017

Nurse Staffing, Allied Staffing, Locum Tenens, Leadership Search, Workforce Tech

AMN EPS (Earnings per Share)

EPS Growth (3Y CAGR): -69.60%
EPS Trend (3Y Correlation): -98.2%

AMN Revenue

Revenue Growth (3Y CAGR): -18.07%
Revenue Trend (3Y Correlation): -96.2%

Description: AMN AMN Healthcare October 22, 2025

AMN Healthcare Services, Inc. (NYSE: AMN) delivers technology-enabled staffing and workforce solutions across the U.S. healthcare system, operating through three distinct segments: Nurse & Allied Solutions, Physician & Leadership Solutions, and Technology & Workforce Solutions. The firm’s portfolio spans travel-nurse and local staffing, international nurse placement, allied-health professional deployment, locum tenens and executive search for physicians, as well as language services, vendor-management platforms, and workforce-optimization tools, all marketed under brands such as AMN Healthcare, Nursefinders, and O’Grady Peyton International.

Key performance indicators show the company generated $4.9 billion in revenue for FY 2023, with the Nurse & Allied segment contributing roughly 70 % of total sales and delivering a 12 % year-over-year growth rate-driven by persistent nationwide nursing shortages and rising acute-care census volumes. The physician-staffing business is expanding at a faster 18 % pace, reflecting increased reliance on locum tenens amid physician retirements. A sector-wide catalyst is the projected 5 % annual increase in U.S. healthcare spending, which underpins demand for flexible staffing and technology-enabled workforce management.

For a deeper dive into AMN’s valuation dynamics and how its growth drivers compare to peers, a quick look at ValueRay’s analytical tools can help you surface the most relevant data points.

AMN Stock Overview

Market Cap in USD	755m
Sub-Industry	Health Care Services
IPO / Inception	2001-11-13

AMN Stock Ratings

Growth Rating	-83.7%
Fundamental	28.1%
Dividend Rating	1.31%
Return 12m vs S&P 500	-61.7%
Analyst Rating	3.33 of 5

AMN Dividends

Currently no dividends paid

AMN Growth Ratios

Growth Correlation 3m	6.2%
Growth Correlation 12m	-79.9%
Growth Correlation 5y	-71.8%
CAGR 5y	-46.22%
CAGR/Max DD 3y (Calmar Ratio)	-0.53
CAGR/Mean DD 3y (Pain Ratio)	-0.87
Sharpe Ratio 12m	-2.09
Alpha	-61.14
Beta	0.148
Volatility	110.73%
Current Volume	3242.2k
Average Volume 20d	664.5k
Stop Loss	16.8 (-6%)
Signal	0.16

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income (-297.8m TTM) > 0 and > 6% of Revenue (6% = 166.2m TTM)

FCFTA 0.12 (>2.0%) and ΔFCFTA 4.15pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -0.08% (prev 4.05%; Δ -4.13pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.14 (>3.0%) and CFO 310.7m > Net Income -297.8m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 1.00 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (38.4m) change vs 12m ago 0.47% (target <= -2.0% for YES)

Gross Margin 29.84% (prev 28.16%; Δ 1.68pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 111.2% (prev 116.7%; Δ -5.51pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -5.25 (EBITDA TTM -157.4m / Interest Expense TTM 61.2m) >= 6 (WARN >= 3)

Altman Z'' 1.65

(A) -0.00 = (Total Current Assets 571.4m - Total Current Liabilities 573.6m) / Total Assets 2.21b

(B) 0.54 = Retained Earnings (Balance) 1.19b / Total Assets 2.21b

(D) 0.74 = Book Value of Equity 1.19b / Total Liabilities 1.60b

Total Rating: 1.65 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 28.06

1. Piotroski 4.0pt = -1.0

2. FCF Yield 15.31% = 5.0

3. FCF Margin 9.22% = 2.31

4. Debt/Equity 1.57 = 1.38

5. Debt/Ebitda -5.11 = -2.50

6. ROIC - WACC (= -19.24)% = -12.50

7. RoE -40.80% = -2.50

8. Rev. Trend -96.24% = -7.22

9. EPS Trend -98.16% = -4.91

What is the price of AMN shares?

As of November 09, 2025, the stock is trading at USD 17.87 with a total of 3,242,169 shares traded.
Over the past week, the price has changed by -9.24%, over one month by -7.89%, over three months by +5.61% and over the past year by -56.33%.

Is AMN Healthcare a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, AMN Healthcare (NYSE:AMN) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 28.06 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AMN is around 10.83 USD . This means that AMN is currently overvalued and has a potential downside of -39.4%.

Is AMN a buy, sell or hold?

AMN Healthcare has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold AMN.

Strong Buy: 1
Buy: 2
Hold: 5
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the AMN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	20.6	15.1%
Analysts Target Price	20.6	15.1%
ValueRay Target Price	11.5	-35.5%

AMN Fundamental Data Overview November 04, 2025

Market Cap USD = 754.6m (754.6m USD * 1.0 USD.USD)
P/E Forward = 18.018
P/S = 0.2724
P/B = 1.2331
P/EG = 1.7113
Beta = 0.148
Revenue TTM = 2.77b USD
EBIT TTM = -321.7m USD
EBITDA TTM = -157.4m USD
Long Term Debt = 916.5m USD (from longTermDebt, last quarter)
Short Term Debt = 12.6m USD (from shortTermDebt, last quarter)
Debt = 955.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 805.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.67b USD (754.6m + Debt 955.8m - CCE 41.5m)
Interest Coverage Ratio = -5.25 (Ebit TTM -321.7m / Interest Expense TTM 61.2m)
FCF Yield = 15.31% (FCF TTM 255.5m / Enterprise Value 1.67b)
FCF Margin = 9.22% (FCF TTM 255.5m / Revenue TTM 2.77b)
Net Margin = -10.75% (Net Income TTM -297.8m / Revenue TTM 2.77b)
Gross Margin = 29.84% ((Revenue TTM 2.77b - Cost of Revenue TTM 1.94b) / Revenue TTM)
Gross Margin QoQ = 29.84% (prev 28.73%)
Tobins Q-Ratio = 0.75 (Enterprise Value 1.67b / Total Assets 2.21b)
Interest Expense / Debt = 1.19% (Interest Expense 11.4m / Debt 955.8m)
Taxrate = 13.97% (-18.9m / -135.1m)
NOPAT = -276.7m (EBIT -321.7m * (1 - 13.97%)) [loss with tax shield]
Current Ratio = 1.00 (Total Current Assets 571.4m / Total Current Liabilities 573.6m)
Debt / Equity = 1.57 (Debt 955.8m / totalStockholderEquity, last quarter 607.6m)
Debt / EBITDA = -5.11 (negative EBITDA) (Net Debt 805.0m / EBITDA -157.4m)
Debt / FCF = 3.15 (Net Debt 805.0m / FCF TTM 255.5m)
Total Stockholder Equity = 730.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -13.46% (Net Income -297.8m / Total Assets 2.21b)
RoE = -40.80% (Net Income TTM -297.8m / Total Stockholder Equity 730.0m)
RoCE = -19.54% (EBIT -321.7m / Capital Employed (Equity 730.0m + L.T.Debt 916.5m))
RoIC = -15.77% (negative operating profit) (NOPAT -276.7m / Invested Capital 1.75b)
WACC = 3.47% (E(754.6m)/V(1.71b) * Re(6.56%) + D(955.8m)/V(1.71b) * Rd(1.19%) * (1-Tc(0.14)))
Discount Rate = 6.56% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.32%
[DCF Debug] Terminal Value 76.03% ; FCFE base≈235.3m ; Y1≈204.2m ; Y5≈163.1m
Fair Price DCF = 77.53 (DCF Value 2.97b / Shares Outstanding 38.3m; 5y FCF grow -16.15% → 3.0% )
EPS Correlation: -98.16 | EPS CAGR: -69.60% | SUE: -1.70 | # QB: 0
Revenue Correlation: -96.24 | Revenue CAGR: -18.07% | SUE: 0.44 | # QB: 0

Additional Sources for AMN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle